Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Sorger, H; Dey, S; Vieyra-Garcia, PA; Poloske, D; Teufelberger, AR; de Araujo, ED; Sedighi, A; Graf, R; Spiegl, B; Lazzeri, I; Braun, T; Alonso, IGD; Schlederer, M; Timelthaler, G; Kodajova, P; Pirker, C; Surbek, M; Machtinger, M; Graier, T; Perchthaler, I; Pan, Y; Fink-Puches, R; Cerroni, L; Ober, J; Otte, M; Albrecht, JD; Tin, G; Abdeldayem, A; Manaswiyoungkul, P; Olaoye, OO; Metzelder, ML; Orlova, A; Berger, W; Wobser, M; Nicolay, JP; Andre, F; Nguyen, V; Neubauer, HA; Fleck, R; Merkel, O; Herling, M; Heitzer, E; Gunning, PT; Kenner, L; Moriggl, R; Wolf, P.
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma
EMBO MOL MED. 2022; Doi: 10.15252/emmm.202115200
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Dey Saptaswa
Wolf Peter
Co-Autor*innen der Med Uni Graz
Cerroni Lorenzo
Fink-Puches Regina
Graf Ricarda
Graier Thomas
Heitzer Ellen
Lazzeri Isaac
Pan Yi
Perchthaler Isabella
Spiegl Benjamin Gernot
Teufelberger Andrea Renate
Vieyra Garcia Pablo Augusto
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Leukemic cutaneous T-cell lymphomas (L-CTCL) are lymphoproliferative disorders of skin-homing mature T-cells causing severe symptoms and high mortality through chronic inflammation, tissue destruction, and serious infections. Despite numerous genomic sequencing efforts, recurrent driver mutations have not been identified, but chromosomal losses and gains are frequent and dominant. We integrated genomic landscape analyses with innovative pharmacologic interference studies to identify key vulnerable nodes in L-CTCL. We detected copy number gains of loci containing the STAT3/5 oncogenes in 74% (n = 17/23) of L-CTCL, which correlated with the increased clonal T-cell count in the blood. Dual inhibition of STAT3/5 using small-molecule degraders and multi-kinase blockers abolished L-CTCL cell growth in vitro and ex vivo, whereby PAK kinase inhibition was specifically selective for L-CTCL patient cells carrying STAT3/5 gains. Importantly, the PAK inhibitor FRAx597 demonstrated encouraging anti-leukemic activity in vivo by inhibiting tumor growth and disease dissemination in intradermally xenografted mice. We conclude that STAT3/5 and PAK kinase interaction represents a new therapeutic node to be further explored in L-CTCL.

Find related publications in this database (Keywords)
lymphoma
STAT3
STAT5
targeting
T-cell
© Med Uni Graz Impressum